Spesolimab improves patient‐reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study
暂无分享,去创建一个
M. Lebwohl | A. Navarini | J. Prinz | M. Viguier | M. Sivalingam | A. Morita | T. Tsai | C. Thoma | L. Li
[1] K. Eyerich,et al. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey , 2022, American Journal of Clinical Dermatology.
[2] M. Lebwohl,et al. Trial of Spesolimab for Generalized Pustular Psoriasis. , 2021, The New England journal of medicine.
[3] M. Lebwohl,et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare , 2021, BMJ Open.
[4] B. Strober,et al. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists , 2021, Dermatology and Therapy.
[5] M. Schaarschmidt,et al. Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study , 2021, Dermatologic therapy.
[6] A. Slade,et al. The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders , 2020, Journal of Patient-Reported Outcomes.
[7] D. Revicki,et al. Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis , 2020, The Journal of dermatological treatment.
[8] H. Bachelez. Pustular Psoriasis: The Dawn of a New Era , 2020, Acta dermato-venereologica.
[9] B. Strober,et al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry , 2020, The Journal of dermatological treatment.
[10] M. Lebwohl,et al. An update on generalized pustular psoriasis , 2019, Expert review of clinical immunology.
[11] M. Akiyama,et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP , 2018, The Journal of dermatology.
[12] T. Bieber,et al. Successful treatment with interleukin‐17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations , 2018, The Journal of dermatology.
[13] H. Nakagawa,et al. Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study , 2018, The Journal of dermatology.
[14] C. Gabay,et al. Regulation and function of interleukin‐36 cytokines , 2018, Immunological reviews.
[15] D. Mennerich,et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies , 2017, mAbs.
[16] H. Nakagawa,et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J) , 2016, The Journal of dermatology.
[17] L. Naldi,et al. European consensus statement on phenotypes of pustular psoriasis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] A. Gnanasakthy,et al. Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development , 2017, The Patient - Patient-Centered Outcomes Research.
[19] H. Nakagawa,et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study , 2016, The Journal of dermatology.
[20] A. Finlay,et al. Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data , 2015, Dermatology.
[21] N. Lai,et al. Clinical profile, morbidity, and outcome of adult‐onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia , 2014, International journal of dermatology.
[22] M. Lebwohl,et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2012, Journal of the American Academy of Dermatology.
[23] A. Smahi,et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.
[24] J. Ortonne,et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy , 2011, The British journal of dermatology.
[25] A. Gottlieb,et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks , 2007, The British journal of dermatology.
[26] D. Cella,et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.
[27] I. Stiell,et al. Clinically important change in the visual analog scale after adequate pain control. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[28] G. Guyatt,et al. Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.